Meanwhile, expression of immune checkpoint genes such as CTLA4, HAVCR2, and TIGIT are reduced in T cells from recurrent tumors compared to the primary tumors, suggesting that checkpoint blockade approaches may be effective in primary HCC but not in recurrent tumors. This evidence concerns the gene TIGIT and hepatocellular carcinoma.